MEDXFMEDXFOTC
Loading
EBITDA Margin Over TimeStrong
Percentile Rank85
3Y CAGR-7.7%
5Y CAGR+3.0%
Studio
Year-over-Year Change

EBITDA as a percentage of revenue

3Y CAGR
-7.7%/yr
Annual compound
5Y CAGR
+3.0%/yr
Recent deceleration
Percentile
P85
Within normal range
vs 5Y Ago
1.2x
Modest growth
Streak
1 yr
Consecutive declineStrong
PeriodValueYoY Change
202515.52%-9.0%
202417.05%+25.8%
202313.55%-31.5%
202219.77%+166.7%
2021-29.63%-320.9%
202013.42%+2040.2%
20190.63%+102.4%
2018-26.64%-77.7%
2017-14.99%+62.4%
2016-39.84%-